title: Advances in sarcoma genomics and new therapeutic targets.
abstract: Increasingly, human mesenchymal malignancies are being classified by the abnormalities that drive their pathogenesis. Although many of these aberrations are highly prevalent within particular sarcoma subtypes, few are currently targeted therapeutically. Indeed, most subtypes of sarcoma are still treated with traditional therapeutic modalities, and in many cases sarcomas are resistant to adjuvant therapies. In this Review, we discuss the core molecular determinants of sarcomagenesis and emphasize the emerging genomic and functional genetic approaches that, coupled with novel therapeutic strategies, have the potential to transform the care of patients with sarcoma.
authors.affiliation: Memorial Sloan-Kettering Cancer Center, New York, New York 10065, USA.
authors.forename: Barry S
authors.initials: BS
authors.lastname: Taylor
authors.forename: Jordi
authors.initials: J
authors.lastname: Barretina
authors.forename: Robert G
authors.initials: RG
authors.lastname: Maki
authors.forename: Cristina R
authors.initials: CR
authors.lastname: Antonescu
authors.forename: Samuel
authors.initials: S
authors.lastname: Singer
authors.forename: Marc
authors.initials: M
authors.lastname: Ladanyi
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use; D016678:Genome; D023281:Genomics; D006801:Humans; D051379:Mice; D009154:Mutation; D012509:Sarcoma / Q000188:drug therapy / Q000235:genetics*; D015398:Signal Transduction
chemical_list: D000970:Antineoplastic Agents